Russian Journal of Bioorganic Chemistry

, Volume 45, Issue 6, pp 783–792 | Cite as

Tumor Specific Peptides Selected for Targeted Delivery of Therapeutic Agents to Glioma Human Cells

  • A. A. Voitova
  • M. D. Dmitrieva
  • M. A. DymovaEmail author
  • N. S. Vasileva
  • A. A. Nushtaeva
  • V. A. Richter
  • E. V. Kuligina


Brain tumors are among the most intractable types of malignant neoplasms. Despite advances in the treatment of cancer, in particular, the development of new approaches in surgery, radiotherapy and chemotherapy, the incidence remains high with a low 5-year survival rate. Targeted therapy (TT) may be a solution to the problem of low efficacy of the applied cancer treatment methods. TT is based on the use of drugs that specifically affect specific types of tumors, which allows one to increase the effectiveness of treatment and minimize toxic effects on healthy tissues of the body. The combination of the unique properties of cancer cells allows one to find specific ligands that interact directly with the tumor, and to conduct TT for malignant tumors. Phage display technology is one of the promising approaches to the search for tissue- and/or organ-specific molecules [1]. Combinatorial phage peptide libraries make it possible to obtain highly specific peptides, including for various types of tumors. Currently, such tumor-targeting peptides are considered as means of targeted delivery of therapeutic genes, cytokines, imaging agents, pro-apoptotic peptides, and cytotoxic drugs. The purpose of this work was to obtain from the phage peptide library of bacteriophages exposing peptides, which ensure the accumulation of phage particles in human glioblastoma cells U-87 MG, and to assess the specificity of the selected peptides for cells of the primary cultures of human gliomas. During the research, the following tasks were solved: (1) Tumor-targeting peptides were selected using human glioblastoma cells U-87 MG in vitro and on a U-87 MG tumor in a xenograft model in vivo; amino acid sequences of selected peptides (SWTFGVQFALQH (26), HPSSGSA (92), PVSNKMS (83)) were determined; (2) primary cultures of human gliomas AS2, MG1, MG2, MG3, MG4 cells were obtained and characterized; (3) specificity of the binding of bacteriophages exposing selected tumor-targeting peptides to cells of primary cultures of human gliomas was evaluated using immunocytochemical analysis. The specific binding of selected tumor-targeting peptides with cells of the primary cultures AS2, MG1 was shown.


phage display tumor-specific peptides astrocytoma glioblastoma immunocytochemical analysis 



The authors thank R.I. Baiborodin, the Head of the Core Facilities Center “Microscopic Analysis of Biological Objects,” SB RAS, for assistance in conducting confocal microscopy.


This study was supported by the Russian Science Fund (grant no. 19-44-02006). We also acknowledge Russian State funded budget project of ICBFM SB RAS АААА-А17-117020210023-1 for supporting this work.


All applicable international, national, and/or institutional ethical standards were followed.

Conflict of Interests

The authors declare that they have no conflict of interest.


  1. 1.
    Kehoe, J.W. and Kay, B.K., Chem. Rev., 2005, vol. 105, no. 11, pp. 4056–72.CrossRefGoogle Scholar
  2. 2.
    Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., and Jemal, A., Ca—Cancer J. Clin., 2018, vol. 68, no. 6, pp. 394–424.CrossRefGoogle Scholar
  3. 3.
    Komori, T., Neurol. Med. Chir. (Tokyo), 2017, vol. 57, pp. 301–311.CrossRefGoogle Scholar
  4. 4.
    Lara-Velazquez, M., Al-Kharboosh, R., Jeanneret, S., Vazquez-Ramos, C., Mahato, D., Tavanaiepour, D., Rahmathulla, G., and Quinones-Hinojosa, A., Brain Sci., 2017, vol. 7, no. 12, p. E166.Google Scholar
  5. 5.
    Wu, D., Gao, Y., Qi, Y., Chen, L., Ma, Y., and Li, Y., Cancer Lett., 2014, vol. 351, no. 1, pp. 13–22.CrossRefGoogle Scholar
  6. 6.
    Saw, P.E. and Song, E.-W., Protein Cell, 2019, pp. 1–21.Google Scholar
  7. 7.
    Garg, P., J. Cancer Res. Ther. 2019, vol. 15, no. 8, p. 1.CrossRefGoogle Scholar
  8. 8.
    Borgoyakova, M.B. and Karpenko, L.I., Biol. Med., 2015, vol. s2. Scholar
  9. 9.
    Allen, M., Bjerke, M., Edlund, H., Nelander, S., and Westermark, B., Sci. Transl. Med., 2016, vol. 8, no. 354, p. 354.CrossRefGoogle Scholar
  10. 10.
    Lau, J.L. and Dunn, M.K., Bioorg. Med. Chem., 2018, vol. 26, no. 10, pp. 2700–2707.CrossRefGoogle Scholar
  11. 11.
    Marsh, W., Exploiting Phage Display for Development of Novel Cellular Targeting Strategies, New York: Humana Press, 2018.CrossRefGoogle Scholar
  12. 12.
    Nemudraya, A.A., Makartsova, A.A., Fomin, A.S., Nushtaeva, A.A., Koval, O.A., Richter, V.A., and Kuligina, E.V., PLoS One, 2016, vol. 11, no. 8. e0160980.CrossRefGoogle Scholar
  13. 13.
    Soendergaard, M., Newton-Northup, J.R., and Deutscher, S.L., Am. J. Nuclear Med. Mol. Imaging, 2014, vol. 4, no. 6, pp. 561–570.Google Scholar
  14. 14.
    Wickramasinghe, S.N., Cell Biochem. Funct., 1996, vol. 14, no. 1, pp. 75–76.Google Scholar
  15. 15.
    Fischer, A.H., Jacobson, K.A., Rose, J., and Zeller, R., Cold Spring Harbor Protoc., 2008, vol. 2008, no. 6, p. 4986.Google Scholar

Copyright information

© Pleiades Publishing, Ltd. 2019

Authors and Affiliations

  • A. A. Voitova
    • 1
  • M. D. Dmitrieva
    • 1
  • M. A. Dymova
    • 1
    Email author
  • N. S. Vasileva
    • 1
  • A. A. Nushtaeva
    • 1
  • V. A. Richter
    • 1
  • E. V. Kuligina
    • 1
  1. 1.Institute of Chemical Biology and Fundamental Medicine, SB RASNovosibirskRussia

Personalised recommendations